Jazz Pharmaceuticals Reports Record Q1 2026 Earnings with $1.1 Billion Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 39 minutes ago
0mins
Should l Buy JAZZ?
Source: seekingalpha
- Record Revenue: Jazz Pharmaceuticals achieved total revenues of $1.1 billion in Q1 2026, marking the highest in the company's history, primarily driven by the outstanding performance of Xywav, Epidiolex, Modeyso, and Zepzelca, indicating strong growth potential in the market.
- Ziihera Regulatory Progress: The FDA has accepted the sBLA for Ziihera and granted priority review, with an expected approval date of August 25, 2026, and management stated they are ready to launch immediately upon approval, enhancing the company's market position in gastric cancer.
- Xywav Sales Growth: Xywav's net product sales increased by 18% to $408 million, with approximately 425 new patients added and around 16,600 active patients, demonstrating strong demand and an expanding customer base for the product.
- Full-Year Financial Outlook: The company reaffirmed its total revenue guidance for 2026 at $4.25 billion to $4.5 billion, despite anticipating increased competition in the sleep business in the second half of the year, while maintaining an optimistic outlook on the growth potential of multiple products.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JAZZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JAZZ
Wall Street analysts forecast JAZZ stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 208.060
Low
188.00
Averages
218.92
High
263.00
Current: 208.060
Low
188.00
Averages
218.92
High
263.00
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jazz Pharmaceuticals Reports Record Q1 2026 Earnings with $1.1 Billion Revenue
- Record Revenue: Jazz Pharmaceuticals achieved total revenues of $1.1 billion in Q1 2026, marking the highest in the company's history, primarily driven by the outstanding performance of Xywav, Epidiolex, Modeyso, and Zepzelca, indicating strong growth potential in the market.
- Ziihera Regulatory Progress: The FDA has accepted the sBLA for Ziihera and granted priority review, with an expected approval date of August 25, 2026, and management stated they are ready to launch immediately upon approval, enhancing the company's market position in gastric cancer.
- Xywav Sales Growth: Xywav's net product sales increased by 18% to $408 million, with approximately 425 new patients added and around 16,600 active patients, demonstrating strong demand and an expanding customer base for the product.
- Full-Year Financial Outlook: The company reaffirmed its total revenue guidance for 2026 at $4.25 billion to $4.5 billion, despite anticipating increased competition in the sleep business in the second half of the year, while maintaining an optimistic outlook on the growth potential of multiple products.
See More
U.S. Eases Restrictions on Cannabis Medicines, Unlocking Funding Potential
- Funding Flow Outlook: The U.S. Department of Justice's rescheduling of FDA-approved and state-regulated cannabis products facilitates easier access to banking services and tax benefits, which is expected to provide a lifeline to the struggling cannabis industry.
- Accelerated Financing Plans: Ananda Pharma is preparing to raise between $10 million and $20 million in private funding within six months to expedite U.S. regulatory engagement and manufacturing of its non-psychoactive CBD drug.
- Expanded Market Opportunities: IGC Pharma is mid-stage testing a low-dose THC liquid for agitation in Alzheimer's patients, with a market estimated between $1 billion and $10 billion, and the rescheduling is expected to attract more investors despite ongoing banking service limitations.
- Reputation Improvement: BRC Therapeutics' CEO noted that the reclassification has reduced reputational barriers among traditional life sciences investors, potentially lowering development costs and simplifying research processes, thereby advancing cannabis drug development.
See More
Jazz Pharmaceuticals' Ziihera Receives FDA Priority Review
- FDA Priority Review: Jazz Pharmaceuticals' Ziihera has received priority review from the FDA for the first-line treatment of HER2-positive gastric, gastroesophageal junction, and adenocarcinoma, indicating the company's strategic positioning in oncology.
- Supporting Data: The application is backed by positive results from the HERIZON-GEA-01 trial, which evaluated the efficacy of zanidatamab in combination with standard chemotherapy, highlighting the potential market opportunity for this new therapy.
- PDUFA Target Date: The FDA has set a PDUFA target action date of August 25, 2026, and if approved, this could provide Jazz Pharmaceuticals with a new revenue stream, enhancing its competitiveness in the cancer treatment market.
- Stock Performance: Although Jazz's shares closed at $196.52, down 1.72% last Friday, the FDA's priority review may boost investor confidence in the future, potentially driving the stock price upward.
See More
Jazz Pharmaceuticals' Ziihera Receives FDA Priority Review
- FDA Priority Review: Jazz Pharmaceuticals announced that its Ziihera (zanidatamab-hrii) has received FDA Priority Review, with a target action date of August 25, 2026, marking a significant advancement in treatment options for patients with HER2-positive gastric cancer.
- Clinical Trial Support: The application for Ziihera is supported by data from the HERIZON-GEA-01 trial, which involved 914 patients and demonstrated its efficacy when used in combination with standard chemotherapy, potentially changing the treatment paradigm for HER2-positive gastric cancer.
- Breakthrough Therapy Designation: The FDA has granted Ziihera Breakthrough Therapy designation, aimed at expediting its development and review, reflecting the drug's potential to offer substantial improvements on clinically significant endpoints, addressing urgent medical needs for patients.
- Global Clinical Trials: The HERIZON-GEA-01 trial is conducted across approximately 300 trial sites in over 30 countries, evaluating the efficacy of Ziihera in combination with chemotherapy, showcasing its potential for widespread application globally.
See More
Jazz Pharmaceuticals' Ziihera Receives FDA Priority Review
- FDA Priority Review: Jazz Pharmaceuticals announced that its Ziihera (zanidatamab-hrii) has received FDA Priority Review for HER2-positive gastric cancer, with a target action date of August 25, 2026, which will expedite the market availability of this new therapy to meet urgent patient needs.
- Clinical Trial Support: The application is supported by data from the HERIZON-GEA-01 trial involving 914 patients, assessing the efficacy of Ziihera in combination with chemotherapy and the PD-1 inhibitor Tevimbra, demonstrating significant clinical benefits that could change existing treatment standards.
- Breakthrough Therapy Designation: The FDA granted Breakthrough Therapy designation for Ziihera in combination with chemotherapy, aimed at expediting development and review, reflecting the potential substantial improvement in treating HER2-positive advanced gastric cancer and the urgent market demand.
- Global Clinical Trials: The HERIZON-GEA-01 trial is conducted across over 300 sites in more than 30 countries, randomizing patients into three groups to evaluate the efficacy of Ziihera with chemotherapy, showcasing the drug's broad application potential globally.
See More
Jazz Pharmaceuticals to Report Q1 2026 Financial Results on May 5
- Earnings Release Schedule: Jazz Pharmaceuticals will report its Q1 2026 financial results on May 5, 2026, after the U.S. market closes, reflecting the company's commitment to transparency in the biopharma sector.
- Webcast Timing: Management will host a webcast at 4:30 p.m. ET to discuss the financial results and provide a business update, ensuring investors receive timely and critical information.
- Registration Recommendation: Participants are advised to register at least 15 minutes prior to the scheduled webcast to ensure a smooth connection, highlighting the company's emphasis on investor communication.
- Replay Availability: A replay of the webcast will be accessible via the Jazz Pharmaceuticals investor website, allowing investors who cannot attend live to catch up on important updates, thereby enhancing engagement between the company and its investors.
See More
Jazz Pharmaceuticals Reports Record Q1 2026 Earnings with $1.1 Billion Revenue
- Record Revenue: Jazz Pharmaceuticals achieved total revenues of $1.1 billion in Q1 2026, marking the highest in the company's history, primarily driven by the outstanding performance of Xywav, Epidiolex, Modeyso, and Zepzelca, indicating strong growth potential in the market.
- Ziihera Regulatory Progress: The FDA has accepted the sBLA for Ziihera and granted priority review, with an expected approval date of August 25, 2026, and management stated they are ready to launch immediately upon approval, enhancing the company's market position in gastric cancer.
- Xywav Sales Growth: Xywav's net product sales increased by 18% to $408 million, with approximately 425 new patients added and around 16,600 active patients, demonstrating strong demand and an expanding customer base for the product.
- Full-Year Financial Outlook: The company reaffirmed its total revenue guidance for 2026 at $4.25 billion to $4.5 billion, despite anticipating increased competition in the sleep business in the second half of the year, while maintaining an optimistic outlook on the growth potential of multiple products.
See More
U.S. Eases Restrictions on Cannabis Medicines, Unlocking Funding Potential
- Funding Flow Outlook: The U.S. Department of Justice's rescheduling of FDA-approved and state-regulated cannabis products facilitates easier access to banking services and tax benefits, which is expected to provide a lifeline to the struggling cannabis industry.
- Accelerated Financing Plans: Ananda Pharma is preparing to raise between $10 million and $20 million in private funding within six months to expedite U.S. regulatory engagement and manufacturing of its non-psychoactive CBD drug.
- Expanded Market Opportunities: IGC Pharma is mid-stage testing a low-dose THC liquid for agitation in Alzheimer's patients, with a market estimated between $1 billion and $10 billion, and the rescheduling is expected to attract more investors despite ongoing banking service limitations.
- Reputation Improvement: BRC Therapeutics' CEO noted that the reclassification has reduced reputational barriers among traditional life sciences investors, potentially lowering development costs and simplifying research processes, thereby advancing cannabis drug development.
See More
Jazz Pharmaceuticals' Ziihera Receives FDA Priority Review
- FDA Priority Review: Jazz Pharmaceuticals' Ziihera has received priority review from the FDA for the first-line treatment of HER2-positive gastric, gastroesophageal junction, and adenocarcinoma, indicating the company's strategic positioning in oncology.
- Supporting Data: The application is backed by positive results from the HERIZON-GEA-01 trial, which evaluated the efficacy of zanidatamab in combination with standard chemotherapy, highlighting the potential market opportunity for this new therapy.
- PDUFA Target Date: The FDA has set a PDUFA target action date of August 25, 2026, and if approved, this could provide Jazz Pharmaceuticals with a new revenue stream, enhancing its competitiveness in the cancer treatment market.
- Stock Performance: Although Jazz's shares closed at $196.52, down 1.72% last Friday, the FDA's priority review may boost investor confidence in the future, potentially driving the stock price upward.
See More
Jazz Pharmaceuticals' Ziihera Receives FDA Priority Review
- FDA Priority Review: Jazz Pharmaceuticals announced that its Ziihera (zanidatamab-hrii) has received FDA Priority Review, with a target action date of August 25, 2026, marking a significant advancement in treatment options for patients with HER2-positive gastric cancer.
- Clinical Trial Support: The application for Ziihera is supported by data from the HERIZON-GEA-01 trial, which involved 914 patients and demonstrated its efficacy when used in combination with standard chemotherapy, potentially changing the treatment paradigm for HER2-positive gastric cancer.
- Breakthrough Therapy Designation: The FDA has granted Ziihera Breakthrough Therapy designation, aimed at expediting its development and review, reflecting the drug's potential to offer substantial improvements on clinically significant endpoints, addressing urgent medical needs for patients.
- Global Clinical Trials: The HERIZON-GEA-01 trial is conducted across approximately 300 trial sites in over 30 countries, evaluating the efficacy of Ziihera in combination with chemotherapy, showcasing its potential for widespread application globally.
See More
Jazz Pharmaceuticals' Ziihera Receives FDA Priority Review
- FDA Priority Review: Jazz Pharmaceuticals announced that its Ziihera (zanidatamab-hrii) has received FDA Priority Review for HER2-positive gastric cancer, with a target action date of August 25, 2026, which will expedite the market availability of this new therapy to meet urgent patient needs.
- Clinical Trial Support: The application is supported by data from the HERIZON-GEA-01 trial involving 914 patients, assessing the efficacy of Ziihera in combination with chemotherapy and the PD-1 inhibitor Tevimbra, demonstrating significant clinical benefits that could change existing treatment standards.
- Breakthrough Therapy Designation: The FDA granted Breakthrough Therapy designation for Ziihera in combination with chemotherapy, aimed at expediting development and review, reflecting the potential substantial improvement in treating HER2-positive advanced gastric cancer and the urgent market demand.
- Global Clinical Trials: The HERIZON-GEA-01 trial is conducted across over 300 sites in more than 30 countries, randomizing patients into three groups to evaluate the efficacy of Ziihera with chemotherapy, showcasing the drug's broad application potential globally.
See More
Jazz Pharmaceuticals to Report Q1 2026 Financial Results on May 5
- Earnings Release Schedule: Jazz Pharmaceuticals will report its Q1 2026 financial results on May 5, 2026, after the U.S. market closes, reflecting the company's commitment to transparency in the biopharma sector.
- Webcast Timing: Management will host a webcast at 4:30 p.m. ET to discuss the financial results and provide a business update, ensuring investors receive timely and critical information.
- Registration Recommendation: Participants are advised to register at least 15 minutes prior to the scheduled webcast to ensure a smooth connection, highlighting the company's emphasis on investor communication.
- Replay Availability: A replay of the webcast will be accessible via the Jazz Pharmaceuticals investor website, allowing investors who cannot attend live to catch up on important updates, thereby enhancing engagement between the company and its investors.
See More
